Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol

Simple item page
dc.catalogadordfo
dc.contributor.authorMartĂ­nez, Felipe
dc.contributor.authorTaramasco, Carla
dc.contributor.authorEspinoza SepĂșlveda, Manuel Antonio
dc.contributor.authorAcevedo, Johanna
dc.contributor.authorGoic Boroevic, Carolina
dc.contributor.authorNervi Nattero, Bruno
dc.date.accessioned2024-03-27T13:31:57Z
dc.date.available2024-03-27T13:31:57Z
dc.date.issued2024
dc.description.abstractChemotherapy requires careful monitoring, but traditional follow-up approaches face significant challenges that were highlighted by the COVID-19 pandemic. Hence, exploration into telemonitoring as an alternative emerged. The objective is to assess the impact of a telemonitoring platform that provides clinical data to physicians overseeing solid tumor patients, aiming to enhance the care experience. The methodology outlines a parallel-group randomized clinical trial involving recently diagnosed patients with solid carcinomas preparing for curative intent chemotherapy. Eligible adult patients diagnosed with specific carcinoma types and proficient in Spanish, possessing smartphones, will be invited to participate. They will be randomized using concealed allocation sequences into two groups: one utilizing a specialized smartphone application called Contigo for monitoring chemotherapy toxicity symptoms and accessing educational content, while the other receives standard care. Primary outcome assessment involves patient experience during chemotherapy using a standardized questionnaire. Secondary outcomes include evaluating severe chemotherapy-associated toxicity, assessing quality of life, and determining user satisfaction with the application. The research will adhere to intention-to-treat principles. This study has been registered at ClinicalTrials.gov (NCT06077123)
dc.fechaingreso.objetodigital2024-03-27
dc.fuente.origenORCID
dc.identifier.doi10.3390/diagnostics14060619
dc.identifier.eissn2075-4418
dc.identifier.urihttps://doi.org/10.3390/diagnostics14060619
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/84704
dc.identifier.urihttps://www.mdpi.com/2075-4418/14/6/619
dc.information.autorucEscuela de Medicina; Nervi Nattero, Bruno; 0000-0002-3016-7261; 604
dc.information.autorucEscuela de Medicina; Espinoza Sepulveda Manuel Antonio; 0000-0001-9564-9512; 10720
dc.information.autorucEscuela de Medicina; Goic Boroevic Carolina; S/I; 67870
dc.information.autorucEscuela de Medicina; Nervi Nattero Bruno; 0000-0002-3016-7261; 604
dc.issue.numero6
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final12
dc.pagina.inicio1
dc.revistaDiagnostics
dc.rightsacceso abierto
dc.rights.licenseAttribution 4.0 International (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectTelemonitoring
dc.subjectCancer
dc.subjectSurveillance
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleDifferential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol
dc.typeartĂ­culo
dc.volumen14
sipa.codpersvinculados604
sipa.codpersvinculados10720
sipa.codpersvinculados67870
sipa.trazabilidadORCID;2024-03-25
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
diagnostics-14-00619.pdf
Size:
1.48 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
ArtĂ­culos de revistas